Dtsch Med Wochenschr 2008; 133(14): 717-719
DOI: 10.1055/s-2008-1067313
Aktuelle Diagnostik & Therapie | Review article
Pneumologie, Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Herzinsuffizienz bei chronisch-obstruktiver Lungenerkrankung (COPD)

Heart failure in chronic obstructive pulmonary disease (COPD)H. Watz1 , 2 , B. Waschki1 , 2 , A.-M Kirsten 1 , 2 , M. Claussen 1 , H. Magnussen 1 , 2
  • 1Krankenhaus Großhansdorf, Zentrum für Pneumologie und Thoraxchirurgie
  • 2Pneumologisches Forschungsinstitut am Krankenhaus Großhansdorf, Zentrum für Pneumologie und Thoraxchirurgie
Further Information

Publication History

eingereicht: 5.11.2007

akzeptiert: 28.1.2008

Publication Date:
25 March 2008 (online)

Zusammenfassung

Die chronische obstruktive Bronchitis und das Lungenemphysem (engl. „chronic obstructive pulmonary disease”, COPD) haben bedeutsame extrapulmonale Auswirkungen, zu denen die kardiovaskulären Erkrankungen gehören. Eine Herzinsuffizienz ist häufig bei Patienten mit COPD. Die Ätiologie der Herzinsuffizienz bei COPD ist nicht vollständig verstanden. Sie lässt sich möglicherweise auf die Häufung der koronaren Herzerkrankung in dieser Population zurückführen. Zudem zeigen jüngste Daten, dass die diastolische linksventrikuläre Dysfunktion von besonderer Bedeutung für die Herzinsuffizienz bei COPD sein könnte.

Summary

Chronic obstructive pulmonary disease (COPD) has significant extrapulmonary effects, among others, on cardiovascular disease. Heart failure can frequently be found in patients with COPD. Etiology of heart failure in COPD is only poorly understood but may be related to the high frequency of ischemic heart disease in this population. Furthermore, recent data suggest that diastolic left ventricular dysfunction may have a role for heart failure in COPD.

Literatur

  • 1 Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline.  J Card Fail. 2006;  12 10-38
  • 2 Anthonisen N R, Skeans M A, Wise R A, Manfreda J, Kanner R E, Connett J E. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.  Ann Intern Med. 2005;  142 233-239
  • 3 Battaglia M, Pewsner D, Juni P, Egger M, Bucher H C, Bachmann L M. Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: systematic review of test accuracy studies.  Arch Intern Med. 2006;  166 1073-1080
  • 4 Boussuges A, Pinet C, Molenat F. et al . Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study.  Am J Respir Crit Care Med. 2000;  162 670-675
  • 5 Buist A S, McBurnie M A, Vollmer W M. et al . International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study.  Lancet. 2007;  370 741-750
  • 6 Calverley P M, Anderson J A, Celli B. et al . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.  N Engl J Med. 2007;  356 775-789
  • 7 Chatterjee K, Massie B. Systolic and diastolic heart failure: differences and similarities.  J Card Fail. 2007;  13 569-576
  • 8 Cowie M R, Struthers A D, Wood D A. et al . Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care.  Lancet. 1997;  350 1349-1353
  • 9 Curkendall S M, DeLuise C, Jones J K. et al . Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients.  Ann Epidemiol. 2006;  16 63-70
  • 10 Goldberg L R, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction.  Circulation. 2006;  113 2851-2860
  • 11 Hobbs F D, Davis R C, Roalfe A K, Hare R, Davies M K, Kenkre J E. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations.  BMJ. 2002;  324 1498
  • 12 Holguin F, Folch E, Redd S C, Mannino D M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001.  Chest. 2005;  128 2005-2011
  • 13 Jessup M, Brozena S. Heart failure.  N Engl J Med. 2003;  348 2007-2018
  • 14 Jorgensen K, Houltz E, Westfelt U, Nilsson F, Schersten H, Ricksten S E. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema.  Chest. 2003;  124 1863-1870
  • 15 Jorgensen K, Muller M F, Nel J, Upton R N, Houltz E, Ricksten S E. Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study.  Chest. 2007;  131 1050-1057
  • 16 Kjoller E, Kober L, Iversen K, Torp-Pedersen C. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction.  Eur J Heart Fail. 2004;  6 71-77
  • 17 Larsen K O, Sjaastad I, Svindland A, Krobert K A, Skjonsberg O H, Christensen G. Alveolar hypoxia induces left ventricular diastolic dysfunction and reduces phosphorylation of phospholamban in mice.  Am J Physiol Heart Circ Physiol. 2006;  291 H507-H516
  • 18 Le Jemtel T H, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.  J Am Coll Cardiol. 2007;  49 171-180
  • 19 Leuchte H H, Baumgartner R A, Nounou M E. et al . Brain natriuretic peptide is a prognostic parameter in chronic lung disease.  Am J Respir Crit Care Med. 2006;  173 744-750
  • 20 Macchia A, Monte S, Romero M, D’Ettorre A, Tognoni G. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure.  Eur J Heart Fail. 2007;  9 942-948
  • 21 Maisel A S, Krishnaswamy P, Nowak R M. et al . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.  N Engl J Med. 2002;  347 161-167
  • 22 Rabe K F, Hurd S, Anzueto A. et al . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.  Am J Respir Crit Care Med. 2007;  176 532-555
  • 23 Rasche K, Orth M, Kutscha A, Duchna H W. Lungenerkrankungen und Herzfunktion.  Internist (Berl). 2007;  48 276-282
  • 24 Remme W J, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure.  Eur Heart J. 2001;  22 1527-1560
  • 25 Rutten F H, Cramer M J, Grobbee D E. et al . Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease.  Eur Heart J. 2005;  26 1887-1894
  • 26 Rutten F H, Moons K G, Cramer M J. et al . Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study.  BMJ. 2005;  331 1379
  • 27 Scharf S M, Iqbal M, Keller C, Criner G, Lee S, Fessler H E. Hemodynamic characterization of patients with severe emphysema.  Am J Respir Crit Care Med. 2002;  166 314-322
  • 28 Sin D D, Anthonisen N R, Soriano J B, Agusti A G. Mortality in COPD: Role of comorbidities.  Eur Respir J. 2006;  28 1245-1257
  • 29 Swedberg K, Cleland J, Dargie H. et al . Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.  Eur Heart J. 2005;  26 1115-1140
  • 30 Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity.  Am J Respir Crit Care Med. 2007;  epub ahead of pri▾

Dr. Henrik Watz

Pneumologisches Forschungsinstitut am Krankenhaus Großhansdorf, Zentrum für Pneumologie und Thoraxchirurgie

Wöhrendamm 80

22927 Großhansdorf

Phone: 04102/601153

Fax: 04102/601245

Email: h.watz@pulmoresearch.de

    >